LivaNova (NASDAQ:LIVN) Given New $111.00 Price Target at Robert W. Baird

Key Points

• Robert W. Baird raised its LivaNova price target to $111 from $95 and maintained an Outperform rating, implying 17.85% potential upside from the previous close.
• LivaNova beat quarterly expectations, reporting EPS of $1.23 versus estimates of $1.06 and revenue of $393.15 million versus $381.13 million. Revenue increased 9.9% year over year.
• Analyst views are broadly positive: MarketBeat lists a Moderate Buy consensus and an average price target of $99.56, with eight Buy ratings, one Strong Buy, and three Hold ratings.

LivaNova (NASDAQ:LIVN - Get Free Report) had its target price lifted by analysts at Robert W. Baird from $95.00 to $111.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage presently has an "outperform" rating on the stock. Robert W. Baird's target price would indicate a potential upside of 17.85% from the company's previous close.

Several other research firms have also issued reports on LIVN. Zacks Research lowered LivaNova from a "strong-buy" rating to a "hold" rating in a report on Wednesday, August 19th. Raymond James Financial set a $120.00 price target on LivaNova in a report on Wednesday. Barclays upgraded LivaNova to a "strong-buy" rating in a research note on Wednesday, October 7th. Stifel Nicolaus set a $85.00 price target on shares of LivaNova in a research note on Wednesday, August 5th. Finally, Mizuho set a $115.00 target price on shares of LivaNova in a research report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and three have given a Hold rating to the company's stock. Based on data from MarketBeat.com, LivaNova presently has a consensus rating of "Moderate Buy" and a consensus target price of $99.56.

LivaNova Price Performance

LivaNova stock opened at $94.19 on Thursday. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.45 and a quick ratio of 1.21. LivaNova has a one year low of $48.82 and a one year high of $99.38. The stock's 50 day moving average is $78.85 and its 200 day moving average is $73.25. The firm has a market cap of $5.19 billion, a P/E ratio of 22.26 and a beta of 0.91.

LivaNova (NASDAQ:LIVN - Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The company reported $1.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.06 by $0.17. The business had revenue of $393.15 million for the quarter, compared to analyst estimates of $381.13 million. LivaNova had a return on equity of 16.35% and a net margin of 12.82%. The company's quarterly revenue was up 9.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.11 earnings per share. As a group, research analysts expect that LivaNova will post 3.78 EPS for the current year.

Insiders Place Their Bets

In other LivaNova news, Director Brooke Story sold 2,300 shares of LivaNova stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $81.42, for a total transaction of $187,266.00. Following the transaction, the director directly owned 7,488 shares of the company's stock, valued at $609,672.96. The trade was a 23.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Francesco Bianchi sold 3,500 shares of LivaNova stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $78.01, for a total transaction of $273,035.00. Following the sale, the director owned 4,434 shares of the company's stock, valued at approximately $345,896.34. This represents a 44.11% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 7,450 shares of company stock valued at $591,839. Insiders own 0.35% of the company's stock.

Hedge Funds Weigh In On LivaNova

Several hedge funds have recently made changes to their positions in the company. Squarepoint Ops LLC purchased a new position in LivaNova in the second quarter worth $1,418,000. Avidian Wealth Enterprises LLC acquired a new position in shares of LivaNova during the 3rd quarter worth $752,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of LivaNova in the 2nd quarter valued at about $4,053,000. Maverick Capital Ltd. acquired a new stake in shares of LivaNova in the first quarter valued at about $956,000. Finally, Renaissance Technologies LLC boosted its holdings in LivaNova by 15.7% during the first quarter. Renaissance Technologies LLC now owns 183,000 shares of the company's stock worth $11,631,000 after buying an additional 24,900 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

Key Headlines Impacting LivaNova

Here are the key news stories impacting LivaNova this week:

• Positive Sentiment: LivaNova reported Q3 earnings of $1.23 per share, above analyst estimates of $1.03–$1.06 and up from $1.11 a year earlier. Revenue rose 9.9% year over year to $393.2 million, also beating estimates. LivaNova Q3 earnings report
• Positive Sentiment: The company raised its 2026 adjusted EPS guidance to $4.40–$4.50 and forecast revenue growth of 9%–10%, signaling confidence in continued growth. 2026 outlook
• Positive Sentiment: Needham raised its price target to $112 from $93 and maintained a Buy rating, adding to the bullish analyst reaction. Needham rating update
• Neutral Sentiment: LivaNova is exploring entry into neuromodulation for obstructive sleep apnea, which could offer a longer-term growth opportunity, though the report describes an area the company is eyeing rather than a near-term revenue driver. OSA neuromodulation plans

LivaNova Company Profile

LivaNova PLC NASDAQ: LIVN is a medical technology company that develops and manufactures devices and therapies for patients with neurological and cardiovascular conditions. Its products are used by hospitals, physicians and other healthcare providers in markets around the world.

The company's Neuromodulation business is best known for VNS Therapy, which uses an implanted device to deliver electrical stimulation to the vagus nerve. The therapy is used primarily for drug-resistant epilepsy and treatment-resistant depression, subject to applicable regulatory approvals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.